This week Wood Mackenzie, an Edinburgh-based research and consulting firm, reviews recent trends in biotechnology stocks.
The Nasdaq biotechnology index fell sharply in early October, losing 9% of its value following a three-month rally. The decline was influenced by industry-specific events, but also by broad market trends, with the fall being mirrored by other, more general indices. The index recovered to end the period just 0.7% down, driven by licensing deals as well as strong earnings for the year's third quarter reported in November. All told, the index is up 3.6% on the year to date.
Clinical-trials failures contributed to the October fall: Human Genome Sciences of Rockville, Maryland, saw its shares plunge 45% after clinical results showed that its antibody drug candidate LymphoStat-B was ineffective in treating lupus. The drug later partially redeemed the company's share value with encouraging clinical-trials results for rheumatoid arthritis, limiting the loss over the period to 35%. NABI Pharmaceuticals of Boca Raton, Florida, rode out the early fall only to take a 74% nosedive in share value in early November after poor clinical-trials results halted further development of its StaphVax vaccine to prevent dangerous bacterial infections.
The market recovery was supported by deal-making activity. Early last month, Pain Therapeutics of South San Francisco entered a strategic alliance valued at more than $400 million with King Pharmaceuticals of Bristol, Tennessee, to develop an addiction-resistant narcotic painkiller. And in late November, Incyte Pharmaceuticals of Wilmington, Delaware, signed a broad research and development agreement worth up to $800 million with drug giant Pfizer. Despite the November surge, the Nasdaq biotechnology index has significantly underperformed compared with wider market indices in the past month.
Related links
Rights and permissions
About this article
Cite this article
Market Watch. Nature 438, 737 (2005). https://doi.org/10.1038/438737b
Published:
Issue Date:
DOI: https://doi.org/10.1038/438737b